Valuation: Valneva SE

Market Cap 406M 464M 377M 347M 653M 44.74B 663M 4.49B 1.76B 21.89B 1.74B 1.7B 75.62B P/E 2026 *
-5.83x
P/E 2027 * 5.64x
Enterprise Value 534M 610M 496M 456M 859M 58.83B 871M 5.91B 2.31B 28.79B 2.29B 2.24B 99.45B EV / Sales 2026 *
3.52x
EV / Sales 2027 * 1.59x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 week-2.72%
Current month-4.54%
1 month-6.12%
3 months-9.64%
6 months-51.12%
Current year-42.69%
1 week 2.15
Extreme 2.147
2.16
1 month 2.15
Extreme 2.147
2.35
Current year 2.15
Extreme 2.147
5.05
1 year 2.15
Extreme 2.147
5.14
3 years 1.77
Extreme 1.768
6.85
5 years 1.77
Extreme 1.768
28.02
10 years 1.77
Extreme 1.768
28.02
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.72% - - 461M
-4.89%-7.74%-3.35%+9.27% 48.5B
-0.14%-0.76%+378.26%+583.71% 38.97B
+0.39%+2.79%+8.23%+61.99% 35.43B
-1.54%-4.01%+5.95%-13.03% 33.65B
-0.87%-3.19%-1.27%+29.16% 26.58B
-1.28%-6.20% - - 16.82B
-0.67%-0.21%+10.55%+115.31% 15.18B
+1.32%+1.85%+11.40%+15.52% 13.89B
+0.40%-2.79%+3.58%-31.98% 12.76B
Average -0.73%-1.86%+51.67%+96.24% 26.87B
Weighted average by Cap. -1.29%-1.82%+68.45%+121.29%

Financials

2026 *2027 *
Net sales 152M 173M 141M 130M 244M 16.72B 248M 1.68B 657M 8.18B 650M 636M 28.26B 294M 336M 273M 251M 473M 32.38B 480M 3.25B 1.27B 15.84B 1.26B 1.23B 54.74B
Net income -66.01M -75.34M -61.28M -56.31M -106M -7.27B -108M -730M -286M -3.56B -283M -277M -12.29B 70.5M 80.46M 65.45M 60.14M 113M 7.76B 115M 780M 305M 3.8B 302M 296M 13.12B
Net Debt 128M 146M 119M 109M 206M 14.1B 209M 1.42B 554M 6.9B 548M 537M 23.83B 60.02M 68.5M 55.72M 51.2M 96.48M 6.61B 97.9M 664M 260M 3.23B 257M 252M 11.17B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change
22/07/26 €2.155 +0.14%
21/07/26 €2.152 +0.23%
20/07/26 €2.147 0.00%
17/07/26 €2.147 -2.23%
16/07/26 €2.196 -0.50%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.142EUR
Average target price
5.233EUR
Spread / Average Target
+144.32%

Quarterly revenue - Rate of surprise